Why Im Not Arbing The Fresenius Akorn Deal | Latest News RSS feed

Why Im Not Arbing The Fresenius Akorn Deal - Latest News

Why I'm Not Arbing The Fresenius / Akorn Deal

I am not interested in risk-arbing this deal at the current risk/reward profile (6.25% in 1 year). The deal continues to make sense from a strategic perspective for Fresenius, but I think Akorn has ... read more

Corruption Currents: Trump Asserts ‘Absolute Immunity’ in Emoluments Lawsuit

(AM ... if she is not indicted on charges of misusing government funds. (Haaretz) Court documents made public this week show Germany-based healthcare company Fresenius Medical Care & Co. said it found ... read more

Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva

As those who know me will attest, I always am willing to ... you and to your Board why Teva's expression of interest and its beliefs fall far short of convincing us to engage in any further ... read more

Looking for another news?

Jilted Akorn sues Fresenius over deal termination

Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April ... said the investigation "has not found any facts that would ... read more

Akorn CEO says Fresenius is using smear campaign to nix $4.3B deal

(Bloomberg) — Akorn Inc.'s top executive complained Fresenius SE officials are unfairly smearing his firm's reputation as the German company tries to pull out of $4.3 billion deal to to buy the ... ... read more

Akorn Craters 32% On FDA Probe - Time To Buy?

The company announces a probe by Acquirer Fresenius amid FDA allegations. Akorn says it sees no material issues and the deal should ... so I am likely a daytrader in the name looking for some ... read more

Akorn Was Warned About Problems Before Merger, Executive Says

A consultant warned Akorn Inc. before its merger with Fresenius SE about production-line problems that raised questions about the integrity of data it provided to drug regulators, an Akorn executive ... read more

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

while Sandoz has significant ophthalmology overlap with Akorn and would likely not have interest. News of the deal first broke on April 7, when Bloomberg reported that Akron was near a deal with ... read more

Akorn accuses Fresenius of nixing $4.3B deal over buyer's remorse

(Bloomberg) — Fresenius ... Akorn's future, its lawyers said in the lawsuit. Fresenius spokesman Matthias Link said the company walked away from the deal because of because of the data integrity ... read more

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 (Reuters) - A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal ... Akorn’s representations regarding its ... read more

The $4.3 Billion Deal That Blew Up Over Shoddy Drug Production

That’s why the company offered him a $250,000 consulting deal after his ouster ... that Silverberg told subordinates not to investigate how phony data ended up in an FDA submission. Fresenius’s ... read more

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

Fresenius officially abandoned the $34 per share deal for Akorn in April. Akorn did not immediately respond to requests for comment. The company said in its lawsuit last month that Fresenius uncovered ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us